Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
